Masthead comporium

Custom Search
HEALTH
Today's Health Headlines
WASHINGTON (Reuters) - The U.S. government's costs could increase by $2.3 billion in 2018 if Congress and President Donald Trump decide not to fund Obamacare-related payments to health insurers, according to a study released Tuesday by the Kaiser Family Foundation.

WASHINGTON (Reuters) - A congressional vote on a Republican healthcare plan may not come for weeks as leaders in the House of Representatives and the Senate continue negotiations over possible proposals, the White House said on Monday.

(Reuters) - Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

(Reuters Health) - - Mindfulness-based stress reduction programs (MSBR) appear to improve low back pain only slightly, and only temporarily, a review of previous research suggests.

(Reuters Health) - Children in America’s poorest communities have three times the risk of dying from child abuse before age 5 as children in the wealthiest neighborhoods, a new study finds.

(Reuters) - Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

(Reuters Health) - Adults who don't have an increased risk of hepatitis C infection should not be tested for it, the Canadian Task Force on Preventive Health Care recommended today.

Diet and gut bacteria linked with blood clots
Mon, 24 Apr 2017 16:46:59 -0400
(Reuters Health) - Consuming too much choline, a nutrient sold in over-the-counter dietary supplements, can boost the risk for blood clots, researchers warn.

(Reuters Health) - Death of a sibling in childhood is associated with a greater risk of early death in the surviving brother or sister, researchers say.

(Reuters) - Eli Lilly and Co said the combination of its experimental breast cancer drug and a commonly used treatment met the main goal of a late-stage study in an interim analysis, setting the stage for a regulatory submission later this year.

ADVERTISEMENT
Login to access your webmail/portal.
Portal users and mncable users can login below
Browse RSS Feeds
click here when finished
Save Page Layout
loading